Somatic mosaicism of the PI3K-AKT-MTOR pathway is associated with hemimegalencephaly in fetal brains

被引:2
|
作者
Itoh, Kyoko [1 ]
Pooh, Ritsuko [2 ,3 ]
Shimokawa, Osamu [3 ]
Fushiki, Shinji [1 ]
机构
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pathol & Appl Neurobiol, Kyoto, Japan
[2] Fetal Brain Ctr, Fetal Diagnost Ctr, CRIFM Prenatal Med Clin, Osaka, Japan
[3] Ritz Med Co Ltd, Clin Lab, Osaka, Japan
关键词
AKT1; hemimegalencephaly; heterotopia; PIK3CA; polymicrogyria; MUTATIONS CAUSE; SPECTRUM; MTOR;
D O I
10.1111/neup.12875
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It is known that somatic activation of PI3K-AKT-MTOR signaling causes malformations of cortical development varying from hemimegalencephaly to focal cortical dysplasia. However, there have been few reports of fetal cases. Here we report two fetal cases of hemimegalencephaly, one associated with mosaic mutations in PIK3CA and another in AKT1. Both brains showed polymicrogyria, multiple subarachnoidal, subcortical, and subventricular heterotopia resulting from abnormal proliferation of neural stem/progenitor cells, cell differentiation, and migration of neuroblasts. Scattered cell nests immunoreactive for phosphorylated-S6 ribosomal protein (P-RPS6) (Ser240/244) were observed in the polymicrogyria-like cortical plate, intermediate zone, and arachnoid space, suggesting that the PI3K-AKT-MTOR pathway was actually activated in these cells. Pathological analyses could shed light on the mechanisms involved in disrupted brain development in the somatic mosaicism of the PI3K-AKT-MTOR pathway.
引用
收藏
页码:190 / 196
页数:7
相关论文
共 50 条
  • [1] Somatic mosaicism of the PI3K-AKT-MTOR pathway causes hemimegalencephaly: Analyses of human fetal cases and animal models
    Itoh, K.
    Tonosaki, M.
    Fushiki, S.
    BRAIN PATHOLOGY, 2023, 33
  • [2] PI3K-AKT-mTOR pathway inhibitors
    Cortot, A
    Armand, JP
    Soria, JC
    BULLETIN DU CANCER, 2006, 93 (01) : 19 - 26
  • [3] PI3K-AKT-mTOR pathway and cancer
    Coutte, Laetitia
    Dreyer, Chantal
    Sablin, Marie-Paule
    Faivre, Sandrine
    Raymond, Eric
    BULLETIN DU CANCER, 2012, 99 (02) : 173 - 180
  • [4] PI3K-AKT-mTOR
    Besse, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S14 - S14
  • [5] De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
    Jeong Ho Lee
    My Huynh
    Jennifer L Silhavy
    Sangwoo Kim
    Tracy Dixon-Salazar
    Andrew Heiberg
    Eric Scott
    Vineet Bafna
    Kiley J Hill
    Adrienne Collazo
    Vincent Funari
    Carsten Russ
    Stacey B Gabriel
    Gary W Mathern
    Joseph G Gleeson
    Nature Genetics, 2012, 44 : 941 - 945
  • [6] De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
    Lee, Jeong Ho
    My Huynh
    Silhavy, Jennifer L.
    Kim, Sangwoo
    Dixon-Salazar, Tracy
    Heiberg, Andrew
    Scott, Eric
    Bafna, Vineet
    Hill, Kiley J.
    Collazo, Adrienne
    Funari, Vincent
    Russ, Carsten
    Gabriel, Stacey B.
    Mathern, Gary W.
    Gleeson, Joseph G.
    NATURE GENETICS, 2012, 44 (08) : 941 - +
  • [7] The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
    Saji, Motoyasu
    Ringel, Matthew D.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2010, 321 (01) : 20 - 28
  • [8] Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
    Yap, Timothy A.
    Garrett, Michelle D.
    Walton, Mike I.
    Raynaud, Florence
    de Bono, Johann S.
    Workman, Paul
    CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) : 393 - 412
  • [9] Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
    Busaidy, Naifa L.
    Farooki, Azeez
    Dowlati, Afshin
    Perentesis, John P.
    Dancey, Janet E.
    Doyle, Laurence A.
    Brell, Joanna M.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (23) : 2919 - 2928
  • [10] Comprehensive analysis of the PI3K-Akt-mTOR pathway in epithelial ovarian carcinoma
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Oumi, Nao
    Kato, Misaki
    Shoji, Tadahiro
    Saga, Yasushi
    Fujiwara, Hiroyuki
    Shimada, Muneaki
    Sugiyama, Toru
    Suzuki, Mitsuaki
    Kigawa, Junzo
    Harada, Tasuku
    CANCER RESEARCH, 2014, 74 (19)